References
- Jaroslawski S , Toumi M . Market access agreements for pharmaceuticals in Europe: Diversity of approaches and underlying concepts. BMC Health Serv Res. 2011; 11: 259.
- Carlson JJ , Sullivan SD , Garrison LP , Neumann PJ , Veenstra DL . Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010; 96(3): 179–90.
- Garrison LP Jr , Towse A , Briggs A , de Pouvourville G , Grueger J , Mohr PE et al. . Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013; 16(5): 703–19. [PubMed Abstract].
- Adamski J , Godman B , Ofierska-Sujkowska G , Osinska B , Herholz H , Wendykowska K et al. . Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payers. BMC Health Serv Res. 2010; 10: 153. [PubMed Abstract] [PubMed CentralFull Text].
- Gertler PM , Martinez S , Premand P , Rawlings LB , Vermeersch CMJ . Impact evaluation in practice. 2010; Washington, DC: The International Bank for Reconstruction and Development/The World Bank.
- Contandriopoulos A-P , Champagne F , Denis J-L , Pineault R . L′évaluation dans le domaine de la santé: Concepts et méthodes. Bulletin. 1993; 33(1): 12–17.
- General Accounting Office US . Designing evaluations. 1991; Washington, DC: US General Accounting Office.
- Gridchyna I . Utilisation de la norme juridique comme instrument de régulation du marché des médicaments innovants en Europe et en France. 2012; Bordeaux: Université Bordeaux 2.
- Rubin D . Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974; 66(5): 688–701.
- Misdrahi D , Delgado A , Bouju S , Comet D , Chiariny JF . [Rationale for the use of long-acting injectable risperidone: A survey of French psychiatrists]. Encephale. 2013; 39 Suppl 1: S8–14. [PubMed Abstract].
- Schneeweiss S , Gagne JJ , Glynn RJ , Ruhl M , Rassen JA . Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011; 90(6): 777–90. [PubMed Abstract].
- Becquemont L , Bordet R , Cellier D . La médecine personnalisée: Comment passer du concept à l'integration dans un plan de développement clinique en vue d'une AMM?. Therapie. 2012; 67(4): 339–48. [PubMed Abstract].